domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -89,6 +89,12 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu
 
 WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
+
+If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), then the chronic use assumption may be wrong. Patients who establish exercise habits during a 1-2 year medication window may not need indefinite treatment, fundamentally changing the cost trajectory. The inflationary projection assumes continuous medication; the combination data suggests a time-limited intervention model may be viable.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -77,6 +77,12 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre
 
 WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
+
+Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results.
+
 ---
 
 Relevant Notes:

inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json

@@ -0,0 +1,25 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-18",
+      "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d"
+    ],
+    "rejections": [
+      "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-18"
+}

inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md

@@ -7,9 +7,13 @@ date: 2026-03-01
 domain: health
 secondary_domains: []
 format: review
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -75,3 +79,12 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer
 PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
 WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC
 EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence.
+
+
+## Key Facts
+- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits'
+- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass
+- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced
+- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions
+- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication)
+- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source